These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 32773233)

  • 21. Patient Compliance With Maintenance Intravesical Therapy for Nonmuscle Invasive Bladder Cancer.
    Tapiero S; Helfand A; Kedar D; Yossepowitch O; Nadu A; Baniel J; Lifshitz D; Margel D
    Urology; 2018 Aug; 118():107-113. PubMed ID: 29792974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of intravesical therapy for non-muscle invasive bladder cancer on the accuracy of urine cytology.
    Gupta M; Milbar N; Tema G; Pederzoli F; Chappidi M; Kates M; VandenBussche CJ; Bivalacqua TJ
    World J Urol; 2019 Oct; 37(10):2051-2058. PubMed ID: 30671639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy?
    Golabek T; Palou J; Rodríguez O; Gaya JM; Breda A; Villavicencio H
    World J Urol; 2017 Feb; 35(2):237-243. PubMed ID: 27277599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of the Paris system for reporting urinary cytology with histologic follow-up.
    Rohra P; Ocampo Gonzalez FA; Yan L; Mir F; Furlan K; Basu S; Barua A; Cheng L; Park JW
    Diagn Cytopathol; 2021 Jun; 49(6):691-699. PubMed ID: 33600080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved risk stratification for patients with high-grade urothelial carcinoma following application of the Paris System for Reporting Urinary Cytology.
    Cowan ML; Rosenthal DL; VandenBussche CJ
    Cancer Cytopathol; 2017 Jun; 125(6):427-434. PubMed ID: 28272842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implementing The Paris System for Reporting Urinary Cytology results in a decrease in the rate of the "atypical" category and an increase in its prediction of subsequent high-grade urothelial carcinoma.
    Wang Y; Auger M; Kanber Y; Caglar D; Brimo F
    Cancer Cytopathol; 2018 Mar; 126(3):207-214. PubMed ID: 29278461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Should "suspicious for high-grade urothelial carcinoma" and "positive for high-grade urothelial carcinoma" remain separate categories?
    Nguyen L; Nilforoushan N; Krane JF; Bose S; Bakkar R
    Cancer Cytopathol; 2021 Feb; 129(2):156-163. PubMed ID: 33036060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of urine cytology diagnostic reports before and after the implementation of the Paris System classification system in China.
    Ma C; Zhang L
    Cytopathology; 2020 Sep; 31(5):457-462. PubMed ID: 32246545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p16/Ki-67 dual labeling and urinary cytology results according to the New Paris System for Reporting Urinary Cytology: Impact of extended follow-up.
    Piaton E; Advenier AS; Carré C; Decaussin-Petrucci M; Mège-Lechevallier F; Hutin K; Nennig C; Colombel M; Ruffion A
    Cancer Cytopathol; 2017 Jul; 125(7):552-562. PubMed ID: 28371465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histological grading of carcinoma in situ of the bladder: its clinical significance in patients who underwent intravesical mitomycin C and doxorubicin sequential therapy.
    Sekine H; Fukui I; Yamada T; Yamada T; Kojima S; Ohshima H
    J Urol; 1996 Jan; 155(1):94-8; discussion 98-9. PubMed ID: 7490908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Usefulness of endoscopic evaluation with fluorescence after endovesical BCG in the management of non-invasive bladder tumors].
    Charbit D; Arnoux V; Gobet F; Pasquier D; Descotes JL; Pfister C
    Prog Urol; 2014 Jul; 24(9):551-5. PubMed ID: 24975789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
    Lotan Y; Inman BA; Davis LG; Kassouf W; Messing E; Daneshmand S; Canter D; Marble HT; Joseph AM; Jewell S; Boorjian SA
    J Urol; 2019 Nov; 202(5):920-926. PubMed ID: 31120373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up.
    Järvinen R; Kaasinen E; Rintala E; Group TF
    Scand J Urol Nephrol; 2012 Dec; 46(6):411-7. PubMed ID: 22746387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Voided urine versus bladder washing cytology for detection of urothelial carcinoma: which is better?
    Keller AK; Jensen JB
    Scand J Urol; 2017 Aug; 51(4):290-292. PubMed ID: 28398114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic problems of urine cytology on initial follow-up after intravesical immunotherapy with Calmette-Guérin bacillus for superficial bladder cancer.
    Mack D; Frick J
    Urol Int; 1994; 52(4):204-7. PubMed ID: 8030167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective evaluation of the RT-PCR based urinary marker Bladder Epicheck® as a diagnostic tool in upper urinary tract tumor.
    Palermo M; D'Elia C; Trenti E; Comploj E; Mian C; Schwienbacher C; Heidegger I; Clauser S; Pycha A; Vjaters E
    Minerva Urol Nephrol; 2024 Apr; 76(2):195-202. PubMed ID: 38498297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Upper urothelial tract high-grade carcinoma: comparison of urine cytology and DNA methylation analysis in urinary samples.
    Pierconti F; Martini M; Fiorentino V; Cenci T; Racioppi M; Foschi N; Di Gianfrancesco L; Sacco E; Rossi E; Larocca LM; Bassi PF
    Hum Pathol; 2021 Dec; 118():42-48. PubMed ID: 34582934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atypical Category of the Johns Hopkins Template Has Higher Risk of Malignancy than the Paris System but the Paris System Is More Applicable for Suspicious Category.
    Celik B; Kavas G
    Acta Cytol; 2023; 67(4):425-433. PubMed ID: 36731438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.